DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and
suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake.
Therapeutic approaches for ... Cited by 416 - Related articles - All 10 versions
- ►endojournals.org DJ Drucker - Molecular Endocrinology, 2003 - Endocrine Soc Peptide hormones are secreted from endocrine cells and neurons and exert their actions through
activation of G protein-coupled receptors to regulate a diverse number of physiological systems
including control of energy ... Cited by 228 - Related articles - BL Direct - All 8 versions
- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility and acid secretion,
epithelial integrity, and both nutrient absorption and disposal. These actions are initiated by
activation of specific G ... Cited by 217 - Related articles - BL Direct - All 7 versions
- ►endojournals.org L Farilla, A Bulotta, B Hirshberg, S Li Calzi, N Khoury, H … - Endocrinology, 2003 - Endocrine Soc The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase glucose-dependent
insulin secretion, enhance insulin gene transcription, expand islet cell mass, and inhibit ß-cell
apoptosis in animal models of ... Cited by 218 - Related articles - BL Direct - All 5 versions
W El-Assaad, J Buteau, ML Peyot, C Nolan, R Roduit, S … - Endocrinology, 2003 - Endocrine Soc We have proposed the "glucolipotoxicity" hypothesis in which elevated free fatty acids (FFAs)
together with hyperglycemia are synergistic in causing islet ß-cell damage because high glucose
inhibits fat oxidation and ... Cited by 174 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org J Buteau, S Foisy, E Joly, M Prentki - Diabetes, 2003 - Am Diabetes Assoc We previously provided evidence that glucagon-like peptide 1 (GLP-1) induces pancreatic ß-cell
growth nonadditively with glucose in a phosphatidylinositol (PI) 3-kinase- and protein kinase C
-dependent manner. However, the ... Cited by 147 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org GG Holz - Diabetes, 2004 - Am Diabetes Assoc Recently published studies of islet cell function reveal unexpected features of glucagon-like
peptide-1 (GLP-1) receptor-mediated signal transduction in the pancreatic β-cell. Although GLP-1 is
established to be a cAMP-elevating ... Cited by 127 - Related articles - BL Direct - All 6 versions
J Buteau, W El-Assaad, CJ Rhodes, L Rosenberg, E … - Diabetologia, 2004 - Springer Aims/hypothesis. We have provided evidence that gluca- gon-like peptide-1, a potential therapeutic
agent in the treatment of diabetes, activates phosphatidylinositol-3 kinase/protein kinase B
signalling in the pancreatic beta ... Cited by 113 - Related articles - BL Direct - All 4 versions
- ►endojournals.org DJ Drucker - Endocrinology, 2003 - Endocrine Soc Studies of the natural history of type 2 diabetes inform us that a progressive decline in ß-cell
function is common in diabetic patients independent of the method of treatment (2). Hence, new
approaches are clearly needed that ... Cited by 102 - Related articles - BL Direct - All 4 versions
Q Wang, L Li, E Xu, V Wong, C Rhodes, PL Brubaker - Diabetologia, 2004 - Springer Aims/hypothesis. The incretin hormone glucagon-like peptide-1 augments islet cell mass in vivo by
increas- ing proliferation and decreasing apoptosis of the beta cells. However, the signalling
pathways that mediate these effects ... Cited by 94 - Related articles - BL Direct - All 4 versions
